نتایج جستجو برای: cd30

تعداد نتایج: 1842  

2011
Fabrina M.Gaspal David Withers Manoj Saini Vasileios Bekiaris Fiona M. McConnell Andrea White Mahmood Khan Hideo Yagita Lucy S.K. Walker Graham Anderson Peter J.L. Lane

Our previous studies have implicated signaling through the tumor necrosis family receptors OX40 and CD30 as critical for maintaining CD4 memory responses. We show that signals through both molecules are also required for CD4 effector-mediated autoimmune tissue damage. Under normal circumstances, male mice deficient in the forkhead transcription factor FoxP3, which lack regulatory CD4 T cells, d...

Journal: :Blood 1996
A Pinto D Aldinucci A Gloghini V Zagonel M Degan S Improta S Juzbasic M Todesco V Perin V Gattei F Herrmann H J Gruss A Carbone

The presence of a prominent tissue eosinophilia represents a typical histopathologic hallmark of Hodgkin's disease (HD). To evaluate the putative role of eosinophils on tumor cell regulation in HD, we have analyzed these cells for the functional expression of CD30 ligand (CD30L), a surface molecule able to transduce CD30-mediated proliferation signals on Hodgkin's (H) and Reed-Sternberg (RS) ce...

Journal: :Molecular cancer therapeutics 2015
Robert Chen Jessie Hou Edward Newman Young Kim Cecile Donohue Xueli Liu Sandra H Thomas Stephen J Forman Susan E Kane

Brentuximab vedotin (BV) is an antibody-drug conjugate that specifically delivers the potent cytotoxic drug monomethyl auristatin E (MMAE) to CD30-positive cells. BV is FDA approved for treatment of relapsed/refractory Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL); however, many patients do not achieve complete remission and develop BV-resistant disease. We selected for BV-resistan...

2015
Robert Chen Jessie Hou Edward Newman Young Kim Cecile Donohue Xueli Liu Sandra H. Thomas Stephen J. Forman Susan E. Kane

Brentuximab vedotin (BV) is an antibody–drug conjugate that specifically delivers the potent cytotoxic drug monomethyl auristatin E (MMAE) to CD30-positive cells. BV is FDA approved for treatment of relapsed/refractory Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL); however, many patients do not achieve complete remission and develop BV-resistant disease. We selected for BV-resistan...

2013
Ewa Paszkiewicz-Kozik Jan Walewski

8531 (2009). Monoclonal antibody therapy for classical Hodgkin lymphoma Review: Clinical Trial Outcomes future science groupClin. Invest. (2013) 3(9)90932 Thertulien R, Frankel AE, Evens AM et al. APhase I, open-label, dose-escalation,multidose study of MDX-1401 (defucosylatedhuman antiCD30 monoclonal antibody) inpatients with CD30-positive refractory/relapsed Ho...

2005
Hiromichi TOMEBA Kazuaki TAKEDA Fumiyuki ADACHI

あらまし 高速信号伝送が要求される次世代の移動無線通信では周波数選択性フェージングチャネルの克服が必 要不可欠であり,マルチキャリア符号分割多重アクセス(MC-CDMA)が注目されている.伝送特性を改善する技術 としてアンテナダイバーシチが良く知られている.筆者らはこれまでに送信側にチャネル等化処理を集中できる時 空間符号化送受信ダイバーシチ(STBC-TRD)を提案した.STBC-TRD は,送信チャネル情報を用いて送信信号を符 号化し,受信側で簡単な復号操作を行うことによりダイバーシチ効果を得ることができる.しかし,これまでの提 案では受信アンテナ数が 2 本までに制限されていた.本論文では,4 アンテナ受信を可能とする送信符号化を提案 している.そして,このときの BER 特性を計算機シミュレーションによって明らかにしている.また,時空間符号 化送信ダイバーシチ(STTD)と受...

Journal: :Hematological Oncology 2023

Introduction: EBV-positive diffuse large B-cell lymphoma (EBV+DLBCL) predicts poor prognosis. Studies have found that CD30 expression was more frequent in EBV+DLBCL patients compared to EBV-negative (EBV-) DLBCL and high associated with survivals EBV+DLBCL. All these facts suggested a synergistic effect between EBV infection. Methods: FARAGE GM12878 are type II III latency EBV-infected B cell l...

Journal: :Haematologica 1999
F Vinante M Krampera L Morosato A Rigo S Romagnani G Pizzolo

BACKGROUND AND OBJECTIVE Measles virus infection (MVI) has been reported to be characterized by an imbalanced Th(1/2)-type cytokine profile. CD30 has been proposed as a receptor preferentially associated with the Th(0/2)-type cytokine pattern. The aim of this study was therefore to define the peripheral T lymphocyte cytokine profile and to test which CD30 expression pattern it was associated wi...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید